We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.83%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.15B
AUM Growth
-$403M
Cap. Flow
-$229M
Cap. Flow %
-3.73%
Top 10 Hldgs %
39.96%
Holding
178
New
9
Increased
64
Reduced
62
Closed
12

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$35.2M
2
SYK icon
Stryker
SYK
+$32.7M
3
UNH icon
UnitedHealth
UNH
+$27.9M
4
PODD icon
Insulet
PODD
+$25.5M
5
RMD icon
ResMed
RMD
+$25.5M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$56.7M
2
ARGX icon
argenx
ARGX
+$45.6M
3
INSM icon
Insmed
INSM
+$43.4M
4
BSX icon
Boston Scientific
BSX
+$42.4M
5
HUM icon
Humana
HUM
+$36.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Industrials 0.05%
3 Communication Services 0.02%
4 Technology 0.02%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIDU icon
151
Baidu
BIDU
$36.5B
$173K ﹤0.01%
2,000
– –
WST icon
152
West Pharmaceutical
WST
$25B
$171K ﹤0.01%
520
-350
-40% -$124K
GRMN
153
Garmin
GRMN
$46.3B
$171K ﹤0.01%
1,050
-1,750
-63% -$276K
RARE icon
154
Ultragenyx Pharmaceutical
RARE
$2.66B
$164K ﹤0.01%
+4,000
New +$171K
ARQT icon
155
Arcutis Biotherapeutics
ARQT
$3.42B
$163K ﹤0.01%
+17,500
New +$158K
AUTL
156
Autolus Therapeutics
AUTL
$405M
$113K ﹤0.01%
32,500
– –
GRAL
157
GRAIL Inc
GRAL
$3.02B
$112K ﹤0.01%
+7,266
New +$118K
A icon
158
Agilent Technologies
A
$39.5B
$91.3K ﹤0.01%
704
+164
+30% +$22.9K
NVDA icon
159
NVIDIA
NVDA
$5.06T
$80.9K ﹤0.01%
655
-315
-32% -$31.8K
ORCL icon
160
Oracle
ORCL
$346B
$80.6K ﹤0.01%
571
-106
-16% -$13.2K
MSFT icon
161
Microsoft
MSFT
$2.83T
$80K ﹤0.01%
179
-1
-0.6% -$422
QCOM icon
162
Qualcomm
QCOM
$180B
$77.9K ﹤0.01%
391
-126
-24% -$23.8K
MTD icon
163
Mettler-Toledo International
MTD
$26.9B
$55.9K ﹤0.01%
40
+7
+21% +$9.57K
OABI icon
164
OmniAb
OABI
$296M
$43K ﹤0.01%
11,456
– –
LH icon
165
Labcorp
LH
$23.9B
$38.7K ﹤0.01%
190
+42
+28% +$8.54K
EXAI
166
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$17.1K ﹤0.01%
3,350
+706
+27% +$3.48K
BAX icon
167
Baxter International
BAX
$11.2B
– –
-4,200
Closed -$180K
BMEA icon
168
Biomea Fusion
BMEA
$91.1M
– –
-17,800
Closed -$266K
BMY icon
169
Bristol-Myers Squibb
BMY
$126B
– –
-23,436
Closed -$1.27M
GDX icon
170
VanEck Gold Miners ETF
GDX
$22.9B
– –
-33,000
Closed -$1.04M
IONQ icon
171
IonQ
IONQ
$12.7B
– –
-1,107
Closed -$11.1K
PACB icon
172
Pacific Biosciences
PACB
$435M
– –
-4,592,251
Closed -$17.2M
RGNX icon
173
Regenxbio
RGNX
$656M
– –
-12,000
Closed -$253K
SMPL icon
174
Simply Good Foods
SMPL
$909M
– –
-7,900
Closed -$269K
SPY icon
175
State Street SPDR S&P 500 ETF Trust
SPY
$777B
– –
-6,660
Closed -$3.48M
4 5 6
7
8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2024 Portfolio in Review

As of Q2 2024, Bellevue Group held 178 positions worth $6.15B, down 6.1% from $6.56B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group withdrew a net $229M in Q2 2024, closing 12 positions and reducing 62 holdings. Its most notable exit was Shockwave Medical, Inc. Common Stock, an estimated $34.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Edgewise Therapeutics worth $25.7M.

  • Bellevue Group's largest Q2 2024 buy was Edgewise Therapeutics: 1,428,929 shares worth $25.7M.
  • Bellevue Group added most to Biohaven in Q2 2024, an estimated $35.2M increase.
  • Bellevue Group's biggest Q2 2024 reduction was Intuitive Surgical, cutting an estimated $56.7M.
  • Bellevue Group fully exited Shockwave Medical, Inc. Common Stock in Q2 2024, selling an estimated $34.4M.
  • Bellevue Group's ten largest holdings make up 40% of its $6.15B portfolio in Q2 2024.
  • Bellevue Group opened 9 new positions and closed 12 in Q2 2024.
  • Bellevue Group's portfolio value fell 6.1% quarter-over-quarter to $6.15B.

Based on Bellevue Group's 13F filing for Q2 2024, filed 14 Aug 2024.